ALCON's VEXOL OPHTHALMIC CORTICOSTEROID APPROVED DEC. 30 FOR TREATING POSTOP INFLAMMATION AND ANTERIOR UVEITIS; LAST 1994 NME RECEIVES PRIORITY REVIEW
• By The Pink Sheet
Alcon Labs' corticosteroid Vexol (rimexolone) was approved on Dec. 30 as the last new drug cleared by FDA during calendar year 1994. The 1% rimexolone suspension, designated "1P" (a new molecular entity given priority review), is indicated for treatment of post-operative inflammation following ocular surgery and treatment of anterior uveitis.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.